Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 1982 Feb;106(2):187-203.

Human T-cell malignancies: Correlative clinical, histopathologic, immunologic, and cytochemical analysis of 23 cases

Human T-cell malignancies: Correlative clinical, histopathologic, immunologic, and cytochemical analysis of 23 cases

D M Knowles 2nd et al. Am J Pathol. 1982 Feb.

Abstract

Twenty-three T-cell neoplasms were investigated for their reactivity with the OKT monoclonal antibodies and expression of certain cytochemical markers. Fourteen neoplasms with diverse histopathologic features, T-cell chronic lymphocytic leukemia, mycosis fungoides, the Sézary syndrome, T-immunoblastic sarcoma, and a pleomorphic large-cell lymphoma, expressed the T helper cell phenotype, OKT3+T4+. Nine other neoplasms displayed marked inter- and intra- tumor heterogeneity. Seven of these cases, lymphoblastic lymphoma, T-cell acute lymphoblastic leukemia, and tumors with feature of T-immunoblastic sarcoma or the multilobated lymphoma of Pinkus, expressed intrathymic phenotypes. The other 2 cases, a lymphoblastic lymphoma and a so-called Lennert's lymphoma, expressed the previously undescribed OKT3+T10+ phenotype. These studies demonstrate that the T-cell malignancies are divisible into phenotypes corresponding to normal maturational stages of T-cell differentiation and functionally distinct T-cell subsets. Such studies should provide a basis for understanding the biologic heterogeneity, clinical diversity, and significance of the variable cytomorphologic characteristics of T-cell malignant tumors and assist in the further delineation of normal human T-cell heterogeneity.

PubMed Disclaimer

References

    1. Cancer. 1972 Jan;29(1):157-64 - PubMed
    1. Cancer. 1974 Oct;34(4):1198-229 - PubMed
    1. J Immunol. 1975 Jan;114(1 Pt 1):187-90 - PubMed
    1. Am J Clin Pathol. 1975 Jun;63(6):786-95 - PubMed
    1. Ann Intern Med. 1975 Oct;83(4):534-52 - PubMed

Publication types

MeSH terms

Substances